[HTML][HTML] Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains …

DF Tifrea, S Pal, J Fairman, P Massari, LM de La Maza - npj Vaccines, 2020 - nature.com
Chlamydia trachomatis is the most frequently detected sexually transmitted bacterial
pathogen in the world. Attempts to control these infections with screening programs and …

[HTML][HTML] Recombinant expression of Chlamydia trachomatis major outer membrane protein in E. Coli outer membrane as a substrate for vaccine research

Z Wen, MA Boddicker, RM Kaufhold, P Khandelwal… - BMC microbiology, 2016 - Springer
Background Chlamydia trachomatis is a human pathogen which causes a number of
pathologies, including genital tract infections in women that can result in tubal infertility …

Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.

GO Ifere, Q He, JU Igietseme, GA Ananaba… - … , and infection= Wei …, 2007 - europepmc.org
Background and purpose Genital infections due to Chlamydia trachomatis pose a
considerable public health challenge worldwide and a vaccine is urgently needed to protect …

[HTML][HTML] A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response …

C Cheng, S Pal, D Tifrea, Z Jia, LM de la Maza - Microbes and infection, 2014 - Elsevier
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in the
World and there is a need for a vaccine. To enhance the immunogenicity of a vaccine …

[HTML][HTML] Cell-free production of a functional oligomeric form of a Chlamydia major outer-membrane protein (MOMP) for vaccine development

W He, M Felderman, AC Evans, J Geng… - Journal of Biological …, 2017 - ASBMB
Chlamydia is a prevalent sexually transmitted disease that infects more than 100 million
people worldwide. Although most individuals infected with Chlamydia trachomatis are …

[HTML][HTML] Structural and immunological characterization of novel recombinant MOMP-based chlamydial antigens

G Madico, O Gursky, J Fairman, P Massari - Vaccines, 2017 - mdpi.com
Chlamydia is the most common cause of bacterial sexually transmitted infections worldwide.
While infections resolve with antibiotic treatment, this is often neglected in women due to …

[HTML][HTML] Immunization with a MOMP-Based Vaccine Protects Mice against a Pulmonary Chlamydia Challenge and Identifies a Disconnection between Infection and …

CP O'Meara, CW Armitage, MCG Harvie, P Timms… - PLoS …, 2013 - journals.plos.org
Chlamydia pneumoniae is responsible for up to 20% of community acquired pneumonia and
can exacerbate chronic inflammatory diseases. As the majority of infections are either mild …

Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane …

G Sun, S Pal, J Weiland, EM Peterson, LM de la Maza - Vaccine, 2009 - Elsevier
To compare the ability of a native and a recombinant preparation of the major outer
membrane protein of Chlamydia trachomatis mouse pneumonitis (MoPn; Ct-nMOMP and Ct …

Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen

R Hadad, E Marks, I Kalbina, K Schön, M Unemo… - APMIS, 2016 - Wiley Online Library
The asymptomatic nature of most Chlamydia trachomatis infections and the lack of
appropriate effects by current prevention and management call for vaccine development. We …

[HTML][HTML] Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a …

S Pal, MI Cruz-Fisher, C Cheng, JR Carmichael… - NPJ vaccines, 2020 - nature.com
Implementation of a vaccine is likely the best approach to curtail Chlamydia trachomatis
infections. The aim of this study was to determine the ability of a vaccine formulated with the …